
Anlon Healthcare Limited - IPO
MAINBOARDAnlon Healthcare IPO Details
Anlon Healthcare IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
To be announced |
Anlon Healthcare IPO Reservation
Promoter Holding
Documents
Anlon Healthcare IPO Valuations
Anlon Healthcare Limited Financial Information
Period Ended | 31 Jan 2025 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 160.96 | 128 | 111.55 | 84.97 |
Revenue | 77.37 | 66.69 | 113.12 | 57.54 |
Profit After Tax | 11.96 | 9.66 | 5.82 | -0.11 |
Net Worth | 71.86 | 21.03 | 7.37 | 1.55 |
Reserves and Surplus | 32.01 | 5.03 | -4.63 | -10.24 |
Total Borrowing | 62.39 | 74.56 | 66.39 | 60.32 |
Amount in ₹ Crore |
About Anlon Healthcare IPO
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company’s portfolio includes 65 commercialized products, 28 at the pilot stage, and 49 in laboratory testing.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
Products:
- Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
- Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
As of January 31, 2025, the company had 105 employees (excluding trainees) and 8 contract workers.
Strength Of Anlon Healthcare IPO
Risk Of Anlon Healthcare IPO
Objectives Anlon Healthcare IPO
1. Funding capital expenditure requirements for Proposed Expansion
2. Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
3. Funding the working capital requirements of the Company
4. General corporate purposes
Company Contact Details
Anlon Healthcare Limited
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
Registrar Contact Details
Lead Mangers
Interactive Financial Services Ltd